




1/8

Dimeric ORF2.1 antigen of hepatitis E virus**Figure 1**


2/8

Multimeric antigen of hepatitis A virus**Figure 2**

3/8

Virus-like particle (VLP) of duck hepatitis B virus.**A. Use of anti-DHBV bridge****Figure 3**

4/8

Virus-like particle (VLP) of duck hepatitis B virus.**B Use of anti-analyte bridge****Figure 4**

5/8

Monomeric antigen with second binding site as bridge.

A. Use of second epitope on the analyte antigen




Figure 5

6/8

Monomeric antigen with second binding site as bridge.

B. Use of fusion protein such as MBP with analyte antigen




Figure 6

7/8

Monomeric antigen with ligand binding site as bridge.





Figure 7

8/8

Multimeric antigen of hepatitis A virus.**Figure 8**